Spinogenix has filed a notice of an exempt offering of securities to raise $35 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Spinogenix is raising up to $35,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Spinogenix
In most neurodegenerative diseases we lose connections – synapses between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. Our mission is to create transformative therapeutics for diseases involving synaptic loss and dysfunction. Our approach is focused on regenerating synapses to reverse declines in cognitive and motor function. This approach is unique among the many therapeutics that are being developed for neurodegenerative conditions, which mostly aim to slow the degenerative process. We envision the use of SPGs as a monotherapy or in combination with other therapeutics that target disease-specific degenerative processes.
To learn more about Spinogenix, visit https://spinogenix.com/
Spinogenix Linkedin Page: https://www.linkedin.com/company/spinogenix/
Contact:
Stella Sarraf, Chief Executive Officer
310-853-5695
https://www.linkedin.com/in/stellasarraf/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
